Thursday, June 16, 2011

A glass of CABERNET or MERLOT for a leaky case of AMD

Extract of my guest post at maiBlog, a radiology-focused blog.

"Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness in adults over 50 years age. While 90% of AMD patients have the dry-type AMD (atrophic), it is the wet AMD (exudative), driven by choroidal neovascularization (CNV), which is responsible for severe and acute vision loss in over 90% of the patients. Famous people, like the artist Georgia O’Keefe, entertainer Bob Hope and the author Henry Grunwald have coped with AMD. There are over 1.6 million people with AMD in the United States and about 200,000 people are diagnosed with wet AMD every year

One promising approach in late-stage clinical development is the use of beta-radiation to selectively target the proliferating cells in the macular lesion. A small company 40-miles south of San Francisco called NeoVista in Newark, Calif., is at the forefront of testing an epimacular brachytherapy device in the pivotal CABERNET (CNV Secondary AMD Treated with BEta RadiatioN Epiretinal Therapy) Study. ..."

Click here to read full post at maiBlog.

(Find this post at InternetArchive here.)

Related Post:

Wednesday, June 8, 2011

The Four Percent Lung Cancer Solution

A small group of lung cancer patients, who carry EML4-ALK marker in their tumor genome, can now look forward to a cancer-free future, thanks to a new drug crizotinib being developed by Pfizer.  This group of patients are generally nonsmokers or had given up smoking long ago, but still have the misfortune of coming down with lung cancer.